dr. kris on the impact of bevacizumab biosimilars in lung cancer
Published 4 years ago • 121 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:30
dr. mcbride on the potential impact of bevacizumab biosimilars in oncology
-
1:09
dr. herbst on the bevacizumab biosimilar in lung cancer
-
1:14
dr. kris discusses role of antiangiogenesis in lung cancer
-
5:39
use of bevacizumab for lung cancer
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:14
dr. kris describes the use of genetic testing in lung cancer
-
1:31
dr. kris on search for biomarkers in advanced squamous nsclc
-
2:20
dr. kris on the relay trial in egfr nsclc
-
4:46
bevacizumab in lung cancer
-
1:40
dr. kris on predicting benefit with osimertinib in egfr nsclc
-
0:44
dr. hamilton on the impact of biosimilars in oncology
-
7:40
bevacizumab in nonsquamous lung cancer
-
1:53
dr. kris on the crizotinib clinical trials
-
3:46
what is the role of bevacizumab in stage iv nsclc?
-
7:07
biosimilar use in the treatment of nsclc
-
0:52
dr. offin on potential implications of introducing biosimilars into oncology
-
0:42
dr. cristofanilli on the need for biosimilars in oncology
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
1:25
dr. brahmer on chemoimmunotherapy in patients with nsclc